Artikel
Benefit assessment of medical interventions: an international perspective
Suche in Medline nach
Autoren
Veröffentlicht: | 27. August 2013 |
---|
Gliederung
Text
This presentation will aim to give an overview about benefit assessment for reimbursement decision making from an international perspective. Examples will be used to highlight differences between countries in their legal frameworks, addressing methodological issues, uncertainty, quantification of extent of added benefit, and criteria for decision making. Focus will be on Germany, England/Wales, and the Netherlands, but also international guidance such as from the International Society for Pharmacoeconomics and Outcomes research (ISPOR), the European Network for Health Technology Assessment (EUnetHTA) and the Cochrane Collaboration will be considered. Current topics which are being intensively discussed include what to do when there is very little evidence, value based pricing, and how to make decisions about interventions for rare diseases (orphan drugs), these will also be addressed.